Henagliflozin in Patients With Atrial Fibrillation
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.
Also called NCT05252624
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 100 participants
- Sponsor
- Registry
-
NCT05252624
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT05252624. Randomized; triple masking; primary purpose prevention. Start 2022-09-01 (anticipated); primary completion 2023-09-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Henagliflozin in Patients With Atrial Fibrillation
- Acronym
- HENA-AF
- Condition
- Atrial Fibrillation
- Intervention (Drug)
- placebo
- Intervention (Drug)
- Henagliflozin 5Mg Tab
- Lead sponsor
- Beijing Anzhen Hospital
Record details
- Record id
cardio:ct-nct05252624- Content hash
4d837aac0a6dd3a63ebfb8f01278b57e1df5a739a9b240ba8af30cb6fe950ae3